Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans

Nature Clinical Practice Nephrology

Volumn 4, Issue 10, 2008, Pages 538-549

  Norris, Keith C ^a   Tareen, Naureen ^a   Martins, David ^a   Vaziri, Nosratola D ^b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

African American; Blood pressure; Ethnicity; Hypertension; Kidney disease

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; VITAMIN D;

AFRICAN AMERICAN; ANGIONEUROTIC EDEMA; AWARENESS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CULTURAL FACTOR; DIABETES MELLITUS; DISEASE COURSE; DRUG WITHDRAWAL; EPIDEMIC; ETHNIC GROUP; ETHNICITY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEREDITY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SOCIAL ASPECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

AFRICAN AMERICANS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION, RENAL;

EID: 52949085446     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0909     Document Type: Review

References (101)

1. Levey AS et al. (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100
2. Coresh J et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047
3. Hsu CY et al. (2003) Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 14: 2902-2907
4. Li S et al. (2004) Differences between blacks and whites in the incidence of end-stage renal disease and associated risk factors. Adv Ren Replace Ther 11: 5-13
5. Feehally J (2005) Ethnicity and renal disease. Kidney Int 68: 414-424
6. Hajjar I and Kotchen TA (2003) Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290: 199-206
7. Norris KC and Agodoa LY (2005) Unraveling the racial disparities associated with kidney disease. Kidney Int 68: 914-924
8. Powe NR (2003) To have and have not: health and health care disparities in chronic kidney disease. Kidney Int 64: 763-772
9. Materson BJ et al. (1993) Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328: 914-921
10. Chobanian AV et al. (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA 289: 2560-2572
11. Douglas JG et al. (2003) Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 163: 525-541
12. Saunders E (1990) Tailoring treatment to minority patients. Am J Med 88: 21S-23S
13. Rosamond W et al. (2008) Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117: e25-e146
14. Ong KL et al. (2007) Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49: 69-75
15. Kramer H et al. (2004) Racial/ethnic differences in hypertension and hypertension treatment and control in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens 17: 963-970
16. Knight EL et al. (2003) High-normal blood pressure and microalbuminuria. Am J Kidney Dis 41: 588-595
17. Walker WG et al. (1992) Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects: the MRFIT Research Group. JAMA 268: 3085-3091
18. US Renal Data System (online 2007) USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States [http://www.usrds.org/atlas.htm] (accessed 1 July 2008)
19. Klag MJ et al. (1997) End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 277: 1293-1298
20. Stehman-Breen CO et al. (2003) Racial differences in early-onset renal disease among young adults: the Coronary Artery Risk Development In Young Adults (CARDIA) study. J Am Soc Nephrol 14: 2352-2357
21. Tarver-Carr ME et al. (2002) Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol 13: 2363-2370
22. Suthanthiran M et al. (2000) Transforming growth factor-β1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 97: 3479-3484
23. DeWan AT et al. (2001) A genome scan for renal function among hypertensives: the HyperGEN study. Am J Hum Genet 68: 136-144
24. Freedman BI (2003) Susceptibility genes for hypertension and renal failure. J Am Soc Nephrol 14 (Suppl 2): S192-S194
25. Norris KC et al. (2001) Cocaine use, hypertension and end-stage renal disease. Am J Kidney Dis 38: 523-528
26. Norris KC and Francis CK (2004) Gender and ethnic differences and considerations in cardiovascular risk assessment and prevention in African Americans. In Practical Strategies in Preventing Heart Disease, 415-440 (Eds Wong N et al.) New York: McGraw-Hill
27. Wilson TW and Grim CE (1991) Biohistory of slavery and blood pressure differences in blacks today: a hypothesis. Hypertension 17 (Suppl): I122-I128
28. Curtin PD (1992) The slavery hypothesis for hypertension among African Americans: the historical evidence. Am J Public Health 82: 1681-1686
29. Maseko MJ et al. (2006) Salt intake in an urban, developing South African community. Cardiovasc J S Afr 17: 186-191
30. Sever PS et al. (1980) Blood-pressure and its correlates in urban and tribal Africa. Lancet 2: 60-64
31. Luft FC et al. (1979) Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. Circulation 59: 643-650
32. Laffer CL and Elijovich F (2002) Essential hypertension of Caribbean Hispanics: sodium, renin, and response to therapy. J Clin Hypertens (Greenwich) 4: 266-273
33. Kobori H et al. (2003) Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 41: 592-597
34. Chandramohan G et al. (2008) Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-κB activity in salt-sensitive and -resistant rat kidneys. Am J Nephrol 28: 158-167
35. Hayakawa H et al. (1997) Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 7: 2407-2413
36. Grim CE et al. (2005) Hyperaldosteronism and hypertension: ethnic differences. Hypertension 45: 766-772
37. Bianchi G et al. (1995) Alpha-adducin may control blood pressure both in rats and humans. Clin Exp Pharmacol Physiol Suppl 22: S7-S9
38. Barlassina C et al. (2000) Alpha-adducin polymorphism in hypertensives of South African ancestry. Am J Hypertens 13: 719-723
39. Tiago AD et al. (2001) Association study of eight candidate genes with renin status in mild-to-moderate hypertension in patients of African ancestry. Cardiovasc J S Afr 12: 75-80
40. Schork NJ et al. (2000) Lack of association between a biallelic polymorphism in the adducin gene and blood pressure in whites and African Americans. Am J Hypertens 13: 693-698
41. + channel in essential hypertension. Hypertension 32: 129-137
42. Swift PA and Macgregor GA (2004) Genetic variation in the epithelial sodium channel: a risk factor for hypertension in people of African origin. Adv Ren Replace Ther 11: 76-86
43. Nkeh B et al. (2003) T594M variant of the epithelial sodium channel beta-subunit gene and hypertension in individuals of African ancestry in South Africa. Am J Hypertens 16: 847-852
44. Hollier JM et al. (2006) Epithelial sodium channel allele T594M is not associated with blood pressure or blood pressure response to amiloride. Hypertension 47: 428-433
45. Tiago AD et al. (2002) Angiotensinogen gene promoter region variant modifies body size-ambulatory blood pressure relations in hypertension. Circulation 106: 1483-1487
46. Woodiwiss AJ et al. (2006) Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin. J Hypertens 24: 1057-1064
47. Bhatnagar V et al. (2007) Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens 25: 2082-2092
48. Martins DS and Norris KC (2003) Diagnosis and treatment of secondary hypertension. In International Textbook of Cardiology, 553-562 (Eds Crawford MH and DiMarco JP) London: Mosby International Limited
49. Beeks E et al. (2004) Genetic predisposition to salt-sensitivity: a systematic review. J Hypertens 22: 1243-1249
50. Thiel BA et al. (2003) A genome-wide linkage analysis investigating the determinants of blood pressure in whites and African Americans. Am J Hypertens 16: 151-153
51. Svetkey LP et al. (1997) Preliminary evidence of linkage of salt sensitivity in Black Americans at the beta 2-adrenergic receptor locus. Hypertension 29: 918-922
52. Kotchen TA et al. (2002) Identification of hypertension-related QTLs in African American sib pairs. Hypertension 40: 634-639
53. Zhu H et al. (2006) The G protein-coupled receptor kinase 4 gene modulates stress-induced sodium excretion in black normotensive adolescents. Pediatr Res 60: 440-442
54. The Henry J. Kaiser Family Foundation (online 1 February 2007) Key facts: race, ethnicity and medical care, 2007 update. [http://www.kff.org/ minorityhealth/6069.cfm] (accessed 12 February 2008)
55. Keppel KG et al. (2002) Trends in racial and ethnic-specific rates for the health status indicators: United States, 1990-98. Healthy People 2000 Stat Notes 1-16
56. Duru OK et al. (2007) Health insurance status and hypertension monitoring and control in the United States. Am J Hypertens 20: 348-353
57. Lenfant C (2003) Clinical research to clinical practice-lost in translation? N Engl J Med 349: 868-874
58. Blustein J (2008) Who is accountable for racial equity in health care? JAMA 299: 814-816
59. Norris K and Nissenson AR (2008) Race, gender, and socioeconomic disparities in CKD in the United States. J Am Soc Nephrol 19: 1261-1270
60. Powe NR (2008) Let's get serious about racial and ethnic disparities. J Am Soc Nephrol 19: 1271-1275
61. Smedley BD et al. (Eds; 2003) Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academies Press
62. Smith DB (2005) Racial and ethnic health disparities and the unfinished civil rights agenda. Health Aff (Millwood) 24: 317-324
63. Norris K and Nissenson AR (2008) Racial disparities in chronic kidney disease: tragedy, opportunity, or both? Clin J Am Soc Nephrol 3: 314-316
64. Hebert LA et al. (1997) Effects of blood pressure control on progressive renal disease in blacks and whites: Modification of Diet in Renal Disease Study Group. Hypertension 30: 428-435
65. Lewis EJ et al. (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329: 1456-1462
66. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863
67. Mann JF et al. (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134: 629-636
68. Whelton PK et al. (1996) Recruitment experience in the African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 16: 17S-33S
69. Wright JT Jr et al. (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288: 2421-2431
70. Agodoa LY et al. (2001) Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285: 2719-2728
71. Wright JT Jr et al. (2002) Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 162: 1636-1643
72. Norris K et al. (2006) Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial. Am J Kidney Dis 48: 739-751
73. Shulman NB et al. (1989) Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program: the Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13: I80-I93
74. Leenen FH et al. (2006) Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48: 374-384
75. Gibbs CR et al. (1999) Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 48: 861-865
76. Elliott WJ (1996) Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther 60: 582-588
77. Woo KS and Nicholls MG (1995) High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 40: 141-144
78. Lewis EJ et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860
79. Brenner BM et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869
80. de Zeeuw D et al. (2006) Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int 69: 1675-1682
81. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997
82. Wright JT Jr et al. (2005) Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 293: 1595-1608
83. Rahman M et al. (2005) Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165: 936-946
84. Srivastava S and Beevers DG (2007) Angioplasty for atheromatous renal artery stenosis: current knowledge and trial results awaited. J Hum Hypertens 21: 507-508
85. Mistry S et al. (2007) Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far. J Hum Hypertens 21: 511-515
86. Rocha-Singh K et al. (2005) Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: the ASPIRE-2 study. J Am Coll Cardiol 46: 776-783
87. [No authors listed] (2004) K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease: executive summary. Am J Kidney Dis 43 (Suppl 1): S16-S33
88. Lea J et al. (2005) The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 165: 947-953
89. Balamuthusamy S et al. (2008) Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 155: 791-805
90. Bakris GL et al. (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36: 646-661
91. Martins D and Norris K (2004) Hypertension treatment in African Americans: physiology is less important than sociology. Cleve Clin J Med 71: 735-743
92. Cann HM (1998) Human genome diversity. C R Acad Sci III 321: 443-446
93. Sankar P et al. (2004) Genetic research and health disparities. JAMA 291: 2985-2989
94. Sehgal AR (2004) Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 43: 566-572
95. Cooper RS and Psaty BM (2005) Should ethnicity serve as the basis for clinical trial design? Diversity and inclusiveness should remain the guiding principles for clinical trials. Circulation 112: 3660-3665; discussion 3665-3666
96. st century. Mcgill J Med 10: 53-57
97. UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317: 713-720
98. Jafar TH et al. (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 135: 73-87
99. Nakao N et al. (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: 117-124
100. Rahman M et al. (2006) Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 144: 172-180
101. Bakris GL et al. (2007) Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 72: 879-885